SNSW(SH:688117)2021-10-27 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥85,482,938.78, a decrease of 10.19% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥19,024,936.15, an increase of 83.89% year-on-year[5]. - The net profit excluding non-recurring gains and losses was ¥18,352,139.50, up 93.81% compared to the previous year[5]. - Net profit for the third quarter of 2021 was ¥43,033,916.95, compared to ¥41,656,637.29 in the previous year, representing a growth of approximately 3.3%[23]. - Total operating revenue for the first three quarters of 2021 reached ¥279,121,290.27, an increase from ¥270,905,465.33 in the same period of 2020, reflecting a growth of approximately 0.8%[22]. - Total operating costs for the same period were ¥230,546,720.25, up from ¥223,621,046.30, indicating an increase of about 3.9%[22]. - Basic earnings per share for the reporting period were ¥0.24, an increase of 41.18% year-on-year[6]. - Basic and diluted earnings per share for the third quarter were both ¥0.62, down from ¥0.69 in the same quarter of the previous year[24]. - The company reported a financial income of ¥2,594,587.88, up from ¥1,454,015.01, showing an increase of about 78.3%[22]. - The total comprehensive income for the third quarter was ¥43,033,916.95, consistent with the net profit, indicating no other comprehensive income adjustments[24]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥907,425,796.89, reflecting a growth of 53.03% from the end of the previous year[6]. - As of September 30, 2021, the total current assets amounted to ¥602,984,005.70, a significant increase from ¥336,093,024.41 at the end of 2020, representing an increase of approximately 79.5%[16]. - The total assets of the company as of September 30, 2021, were ¥907,425,796.89, compared to ¥592,984,864.45 at the end of 2020, reflecting an increase of approximately 53.1%[17]. - The company reported a total non-current assets of ¥304,441,791.19, up from ¥256,891,840.04, which is an increase of around 18.4%[17]. - The company's total liabilities decreased from ¥155,410,598.68 to ¥140,785,431.76, a reduction of about 9.4%[22]. - The total liabilities were not explicitly stated, but accounts payable decreased to ¥5,257,078.05 from ¥20,666,627.10, indicating a reduction of approximately 74.6%[17]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥28,604,702.44, down 53.65% compared to the previous year[6]. - Cash inflows from operating activities totaled ¥396,307,890.00 for the first three quarters, compared to ¥370,248,224.86 in the same period of 2020, reflecting an increase of about 7.0%[25]. - The net cash flow from operating activities was $28,604,702.44, a decrease of 53.8% compared to $61,720,516.49 in the previous year[26]. - Total cash outflow from operating activities amounted to $367,703,187.56, up 19.1% from $308,527,708.37 year-over-year[26]. - The net cash flow from investing activities was -$63,765,550.05, compared to -$39,790,550.95 in the same period last year, indicating a significant increase in investment outflows[26]. - Cash inflow from financing activities was $285,016,000, with no cash inflow recorded in the previous year[26]. - The net cash flow from financing activities was $285,016,000, contrasting with a net outflow of $475,309.33 in the previous year[26]. - The total cash and cash equivalents at the end of the period reached $377,808,156.41, a substantial increase from $124,263,977.90 year-over-year[27]. - The cash and cash equivalents net increase for the quarter was $249,551,678.76, compared to $21,314,496.95 in the same quarter last year[27]. - The company reported a cash outflow of $63,765,550.05 from investing activities, primarily due to capital expenditures[26]. Research and Development - Research and development expenses totaled ¥3,418,356.09, a decrease of 58.57% compared to the same period last year[6]. - Research and development expenses for the third quarter were ¥8,920,158.71, a decrease from ¥11,936,006.06 in the previous year, indicating a reduction of approximately 25.3%[22]. - The company has 27 self-developed projects, with 11 projects completed and entering the review stage or about to be reported, and 5 projects in clinical trial stages[10]. - The company has ongoing development expenditures amounting to ¥7,826,561.29, which increased from ¥4,736,120.07, reflecting a growth of about 65.5%[17]. Shareholder Information - The top shareholder, Chengdu Sainuo Investment Co., Ltd., holds 37.50% of the shares, totaling 30,000,000 shares[12]. - The company has no reported financing or margin trading activities among the top shareholders[13].